New Peer-Reviewed Study Demonstrates Amprion's Seed Amplification Assay Can Differentiate Multiple System Atrophy from Parkinson's Disease Using Skin Biopsy Samples
SAN DIEGO--(BUSINESS WIRE)--Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced publication of new peer-reviewed research in npj Parkinson's Disease, a Nature Portfolio journal, demonstrating that its skin-based α-synuclein seed amplification assay (skin SAA) can differentiate multiple system atrophy (MSA) from neuronal synuclein diseases (NSD), including Parkinson's disease (PD) and dementia with Lewy bodies (DLB), rep